YOLFTbeta
WOOJUNG BIO Inc

WOOJUNG BIO Inc

215380 · KQ · Healthcare / Biotechnology

1,824.00KRW+2.00 (+0.11%)

Price History

Full chart

Market Stats

Previous Close1,822.00
Open1,822.00
Day Range1,800.00 – 1,845.00
52-Week Range1,681.00 – 4,535.00
Volume11.10K
Market Cap38.93B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.55
50-Day Avg2,247.40
200-Day Avg2,454.94

About

Kolmar BioTech, Inc. engages in the various research services in South Korea. The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and environmental monitoring, and technical support services. In addition, It offers construction and implementation, infection control, maintenance, laboratory and pharmaceutical equipment, and consumables and animal resourcing services. Kolmar BioTech, Inc. was formerly known as WOOJUNG BIO, Inc. and changed its name to Kolmar BioTech, Inc. in July 2026. The company was founded in 1989 and is based in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOByungSeok Moon
  • Employees0
  • HeadquartersKolmar BioCluster, Hwaseong-si, South Korea, Korea
  • Websitehttps://kolmarbiotech.com

Leadership

  • ByungSeok MoonCEO & Director · b. 1960

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-21.48B28.93B23.76B32.29B37.34B31.24B46.92B38.62B43.20B37.59B
Growth (%)--+34.70%-17.88%+35.91%+15.65%-16.35%+50.20%-17.70%+11.87%-12.99%
Cost of Revenue-14.71B23.05B16.76B22.50B32.04B25.36B40.19B32.33B30.51B27.48B
Gross Profit-6.77B5.88B7.00B9.79B5.30B5.88B6.73B6.29B12.69B10.10B
Gross Margin-31.52%20.32%29.48%30.31%14.19%18.81%14.34%16.29%29.37%26.88%
Operating Expense-6.84B8.32B10.46B9.15B10.60B9.40B10.10B12.56B10.37B13.76B
Operating Income-22.54M-68.37M-2.44B-3.46B642.32M-5.31B-3.53B-3.37B-6.27B2.32B-3.65B
Operating Margin--0.32%-8.42%-14.55%1.99%-14.21%-11.29%-7.18%-16.23%5.37%-9.72%
EBITDA-------5.18B2.49B7.66B1.12B
EBITDA Margin-------11.04%6.46%17.72%2.97%
Net Income57.67M77.25M-6.92B-3.98B279.59M-10.88B-1.93B-1.88B-5.05B225.30M-5.55B
Net Income Margin-0.36%-23.92%-16.74%0.87%-29.13%-6.16%-4.01%-13.09%0.52%-14.76%
R&D-1.34B1.44B1.39B1.14B620.94M538.26M614.06M294.44M505.84M443.61M
R&D as % of Total Revenue-6.26%4.96%5.85%3.52%1.66%1.72%1.31%0.76%1.17%1.18%
Interest Expense000055.41M54.02M648.62M2.80B3.23B3.23B2.89B
Interest Expense % of Total Revenue-0.00%0.00%0.00%0.17%0.14%2.08%5.96%8.35%7.47%7.70%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets12.00B31.40B44.81B57.63B69.82B100.14B94.99B98.33B94.70B86.80B
Total Liabilities1.43B13.07B23.61B30.97B41.78B68.68B65.28B76.36B65.33B63.42B
Total Equity10.57B18.32B21.20B26.66B28.03B31.46B29.72B21.97B29.37B23.38B
Cash2.52B2.26B11.13B4.70B4.11B705.19K15.71K5.42B4.02B3.83B
Total Debt--8.64B2.22B24.80B-----
Net Debt----20.09B37.86B36.71B45.23B46.51B46.35B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.39M-1.46B-2.38B-483.80M208.72M-8.57B1.73B2.50B-3.22B-1.13B-630.50M
Investing Cash Flow-10.00B-2.19B253.74M-2.86B-7.35B-18.22B-29.44B-6.19B135.86M-1.05B-
Financing Cash Flow11.79B3.87B260.27M12.22B707.48M26.25B24.06B6.81B4.93B775.92M-
Capital Expenditure01.33B1.24B4.67B2.16B15.77B36.68B11.42B887.47M309.51M259.30M
Free Cash Flow------25.21B-34.99B-9.01B-4.11B-1.44B-889.79M
FCF to OCF-----294.05%-2025.29%-359.96%127.54%127.48%141.13%

Earnings

Report DateJun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017May 15, 2018Aug 14, 2018Nov 14, 2018Mar 11, 2019May 6, 2019Aug 13, 2019Nov 13, 2019Mar 2, 2020May 15, 2020Aug 14, 2020Nov 16, 2020Feb 10, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------
EPS Actual6.64-3.9529.62-3.5616.15-3.5812.92592.17-881.7532.17-141.27-172.41-133.822.98-122.5068.04-261.07311.18-90.5362.21-61.00-693.00-250.0628.05-104.1641.73-109.73-71.88-265.40-66.80258.39-297.96-129.03-214.45248.48-125.4532.36-67.9630.48-124.80-100.96-36.95-78.61-12.635.82
Surprise---------------------------------------------
Timing-----------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market----------------------

Key Statistics & Ratios

Market Cap38.93B
Enterprise Value55.78B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.97
Price / Book1.43
Revenue (TTM)40.30B
Gross Profit (TTM)11.44B
EBITDA1.88B
Profit Margin-9.12%
Operating Margin3.89%
Return on Equity-14.57%
Return on Assets-1.06%
Shares Outstanding16.67M
Shares Float2.46M
Beta0.55
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 6, 20192:5